Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Daniel, Galimberti"'
Autor:
Daniel Galimberti, Agustina Vila Echague, Ery A. Ko, Laura Pieri, Alessandra Comito, Irene Fusco, Tiziano Zingoni
Publikováno v:
Archivio Italiano di Urologia e Andrologia (2024)
Background: The erectile dysfunction (ED), which is the inability to achieve and/or sustain a penile erection sufficient to result in a satisfying sexual performance, represents a very common complaint. for men over forty years old. The aim of the st
Externí odkaz:
https://doaj.org/article/97a5ed40ccb54b2cb2b09e47a6fad4f9
Autor:
Jorge Máspero, Hugo Cabrera, Ledit Ardusso, Mónica De Gennaro, Ramón Fernández Bussy, José Galimany, Daniel Galimberti, Marcelo Label, Marta La Forgia, Iris Medina, Hugo Neffen, Patricia Troielli
Publikováno v:
Medicina (Buenos Aires), Vol 74, Iss suppl 1, Pp 1-53 (2014)
Se actualiza el diagnóstico de la urticaria crónica (UC) y los conceptos, definiciones y sugerencias basados en la evidencia para su tratamiento. La urticaria ocurre en al menos 20% de la población en algún momento de la vida. Su etiología difie
Autor:
Jorge, Máspero, Hugo, Cabrera, Ledit, Ardusso, Mónica, De Gennaro, Ramón, Fernández Bussy, José, Galimany, Daniel, Galimberti, Marcelo, Label, Marta, La Forgia, Iris, Medina, Hugo, Neffen, Patricia, Troielli
Publikováno v:
Medicina. 74
This interdisciplinary paper summarizes the news in the diagnosis and treatment of chronic urticaria (CU), and provides concepts, definitions and evidence-based suggestions for its management. Urticaria occurs in at least 20% of the population at som
Autor:
Patricia A, Troielli, Beatriz, Asis, Alcira, Bermejo, Mario, Bittar, Hugo, Cabrera, Carla, Castro, Ezequiel, Chouela, Andrés, Cordero, Roberto, Dobrinin, Sergio, Escobar, Mirta, Fortino, Daniel, Galimberti, Gaston, Galimberti, Maria Elsa, Giovo, Beatriz, Gomez, Maria del Carmen, Gras, Mónica, Ibarra, Viviana, Kizlansky, Patricio Martinez, Chabbert, Sergio, Ramonda
Publikováno v:
Skinmed. 8(1)
A new fixed-dose combination formulation of adapalene 0.1% and benzoyl peroxide (BPO) 2.5% has shown excellent efficacy and safety in registration studies; however, it can be difficult to judge the real-world performance of a product using only the r